Skip to Main Content
Back to News

Medicare Star Ratings Recalculated After UnitedHealth (UNH) Court Victory

Quiver Editor

The U.S. Centers for Medicare and Medicaid Services (CMS) announced on Friday that it will not appeal a federal court ruling requiring it to recalculate the star ratings assigned to UnitedHealth Group’s (UNH) Medicare Advantage plans. The decision comes after UnitedHealth argued that the downgrades, based on a single test call for a foreign language interpreter, were unfair and could result in millions of dollars in lost revenue due to reduced consumer enrollment. Shares of UnitedHealth rose 0.6% to $532.86 on the news.

CMS did not explain its decision to drop the appeal, which had been filed just three days earlier. The withdrawal raises speculation about a potential policy shift under President Donald Trump's administration, as federal health agencies are currently under a communication pause ordered by the White House. Other insurers, including Elevance Health, Centene, and Humana, have also challenged CMS star ratings in court, alleging that they were applied unfairly and hurt their business.

Market Overview:
  • CMS dropped its appeal in the UnitedHealth Medicare Advantage star ratings lawsuit.
  • The federal court ruling requires CMS to recalculate star ratings, benefiting insurers.
  • Shares of UnitedHealth rose 0.6% on the announcement.
Key Points:
  • UnitedHealth’s lawsuit focused on the downgrading of star ratings due to a test call error.
  • Other insurers, including Elevance and Centene, have also challenged CMS star ratings.
  • CMS previously recalculated ratings for Elevance after losing a similar court case.
Looking Ahead:
  • Observers speculate whether the move signals broader policy changes under Trump.
  • CMS’s recalculation may improve consumer perceptions of affected Medicare plans.
  • Insurers await potential revisions to the star ratings system following the ruling.
Bull Case:
  • The CMS decision to drop its appeal provides immediate relief to UnitedHealth, ensuring recalculated star ratings that could significantly boost quality bonus payments and consumer enrollment.
  • UnitedHealth’s shares rose 0.6% following the announcement, reflecting investor confidence in the positive financial impact of the recalculated ratings.
  • The court ruling sets a precedent for other insurers like Elevance Health and Centene, potentially leading to broader recalculations that benefit the Medicare Advantage industry.
  • The removal of CMS’s appeal aligns with potential policy shifts under the Trump administration, signaling a more business-friendly regulatory environment for insurers.
  • Improved star ratings enhance consumer perceptions of UnitedHealth’s Medicare Advantage plans, strengthening its competitive position in a growing market.
Bear Case:
  • The CMS decision not to appeal may invite further lawsuits from insurers challenging star ratings, potentially overwhelming the agency and delaying future evaluations.
  • Critics argue that recalculating ratings based on isolated incidents, such as a single test call, undermines the integrity of the Medicare Advantage star rating system.
  • Other insurers like Humana and Centene may push for similar recalculations, creating potential inconsistencies in how CMS evaluates and adjusts ratings across the industry.
  • Speculation about broader policy shifts under the Trump administration introduces regulatory uncertainty, which could complicate long-term planning for insurers like UnitedHealth.
  • While UnitedHealth benefits from this ruling, continued legal challenges and disputes over star ratings could erode public trust in Medicare Advantage plans overall.

The lawsuit centers around Medicare Advantage plans, which are private health insurance plans funded by Medicare for seniors and individuals with disabilities. CMS assigns these plans one- to five-star ratings to guide consumer choice, making the scores critical for attracting enrollees. UnitedHealth had argued that the star downgrade was based on a flawed process, with the court ruling in its favor in November, setting a precedent for similar cases.

The CMS decision not to appeal the UnitedHealth case could influence how star ratings are applied and challenged in the future. Insurers are likely to monitor whether the Trump administration plans any broader reforms to Medicare Advantage oversight. With additional lawsuits from other major players in the industry, the recalculations may have significant implications for both insurers and Medicare beneficiaries.

About the Author

David Love is an editor at Quiver Quantitative, with a focus on global markets and breaking news. Prior to joining Quiver, David was the CEO of Winter Haven Capital.

Add Quiver Quantitative to your Google News feed.Google News Logo

Suggested Articles